TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,018 | -44.0% | 337,614 | -3.7% | 0.03% | -41.2% |
| Q2 2023 | $5,385 | -20.6% | 350,610 | +16.2% | 0.05% | -22.7% |
| Q1 2023 | $6,786 | +33.5% | 301,754 | +24.8% | 0.07% | +26.9% |
| Q4 2022 | $5,084 | -99.9% | 241,734 | -0.9% | 0.05% | -21.2% |
| Q3 2022 | $6,008,000 | +0.6% | 243,838 | -1.1% | 0.07% | +3.1% |
| Q2 2022 | $5,973,000 | -6.8% | 246,526 | -0.9% | 0.06% | +12.3% |
| Q1 2022 | $6,408,000 | -19.2% | 248,671 | -2.7% | 0.06% | -13.6% |
| Q4 2021 | $7,930,000 | +5.3% | 255,476 | -17.7% | 0.07% | -1.5% |
| Q3 2021 | $7,530,000 | +64.0% | 310,518 | -1.3% | 0.07% | +67.5% |
| Q2 2021 | $4,592,000 | -42.8% | 314,749 | -2.0% | 0.04% | -45.9% |
| Q1 2021 | $8,021,000 | -9.3% | 321,234 | -0.9% | 0.07% | -20.4% |
| Q4 2020 | $8,839,000 | – | 324,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |